

# Laura S Kerkmeijer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7599190/publications.pdf>

Version: 2024-02-01

14  
papers

111  
citations

1684188

5  
h-index

1372567

10  
g-index

14  
all docs

14  
docs citations

14  
times ranked

247  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 797-804.	1.7	4
2	Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 89-96.	1.7	4
3	A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial. <i>International Journal of Cardiology</i> , 2020, 300, 93-98.	1.7	4
4	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 21.	6.1	49
5	Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE Registry. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 567-570.	0.8	3
6	Scaffold Resorption Process Is Not the Achilles' Heel of the Absorb BVS. <i>JACC Basic To Translational Science</i> , 2020, 5, 630-631.	4.1	1
7	Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus—AIDA substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 713-720.	1.7	1
8	Final five-year results of the REMEDEE Registry: Real-world experience with the dual-therapy COMBO stent. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 503-510.	1.7	6
9	1-Year Clinical Outcomes of All-Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 820-830.	2.9	10
10	Three-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 342-347.	1.7	8
11	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial. <i>EuroIntervention</i> , 2019, 15, 603-606.	3.2	11
12	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. <i>International Journal of Cardiology</i> , 2018, 263, 24-28.	1.7	6
13	Stent thrombosis in patients with drug-eluting stents and bioresorbable vascular scaffolds. The feared complication. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 52-59.	0.4	2
14	Diabetes mellitus and multivessel coronary artery disease: an ongoing battle for an ideal treatment strategy. <i>Annals of Translational Medicine</i> , 2017, 5, 261-261.	1.7	2